See more : Sichuan Furong Technology Co., Ltd. (603327.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Genexine, Inc. (095700.KQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Genexine, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Hamee Corp. (3134.T) Income Statement Analysis – Financial Results
- Nippon Carbon Co., Ltd. (NCRBF) Income Statement Analysis – Financial Results
- SK hynix Inc. (000660.KS) Income Statement Analysis – Financial Results
- Timbercreek Financial Corp. (TF.TO) Income Statement Analysis – Financial Results
- Automatic Bank Services Limited (SHVA.TA) Income Statement Analysis – Financial Results
Genexine, Inc. (095700.KQ)
About Genexine, Inc.
Genexine, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of immunotherapeutics and long-acting biologics in South Korea. It develops hyFc platform, a proprietary technology designed to drive the discovery of various differentiated agonistic protein therapeutics; and the Immune Enhancing Technology, a therapeutic DNA vaccine technology. The company's product pipeline includes GX-H9, which is in Phase II clinical trials for the treatment of adult and pediatric growth hormone deficiency; GX-E2, which is in Phase II clinical trials for the treatment of induced anemia; GX-G3, which is in Phase II clinical trials to treat neutropenia; and GX-G6 that is in Phase I clinical trials for the treatment of diabetes. It is also developing GX-188E that is in Phase II clinical trials in combination with KEYTRUDA for the treatment of cervical cancer. Genexine, Inc. has a co-development partnership with Binex Co. Ltd. to develop COVID-19 vaccine. The company was formerly known as Genexine Co., Ltd. and changed its name to Genexine, Inc. in March 2013. Genexine, Inc. was founded in 1999 and is based in Seongnam, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.43B | 16.14B | 36.83B | 18.54B | 11.30B | 12.88B | 28.45B | 11.35B | 32.52B | 6.25B |
| Cost of Revenue | 4.12B | 8.83B | 7.68B | 8.99B | 5.74B | 8.61B | 11.41B | 5.61B | 8.44B | 901.62M |
| Gross Profit | 302.04M | 7.30B | 29.15B | 9.55B | 5.56B | 4.27B | 17.04B | 5.74B | 24.08B | 5.35B |
| Gross Profit Ratio | 6.82% | 45.26% | 79.15% | 51.50% | 49.21% | 33.16% | 59.89% | 50.54% | 74.05% | 85.58% |
| Research & Development | 26.33B | 24.72B | 38.39B | 42.59B | 41.47B | 35.82B | 34.92B | 20.14B | 745.25M | 283.31M |
| General & Administrative | 1.90B | 2.49B | 2.24B | 3.12B | 54.00M | 0.00 | 0.00 | 0.00 | 0.00 | 202.59M |
| Selling & Marketing | 5.35B | 2.18B | 1.72B | 1.75B | 1.60B | 0.00 | 0.00 | 0.00 | 0.00 | 819.14M |
| SG&A | 7.25B | 17.00B | 16.24B | 9.91B | 9.90B | 10.14B | 8.84B | 15.86B | 17.42B | 4.32B |
| Other Expenses | 8.05B | 1.91B | 1.98B | -706.48M | -809.37M | -1.07B | -140.71M | -622.19M | -4.83B | 0.00 |
| Operating Expenses | 41.63B | 41.72B | 54.62B | 53.22B | 52.18B | 47.04B | 43.90B | 36.62B | 22.99B | 7.08B |
| Cost & Expenses | 45.67B | 50.55B | 62.30B | 62.21B | 57.92B | 55.65B | 55.31B | 42.24B | 31.43B | 7.98B |
| Interest Income | 1.26B | 243.37M | 219.15M | 252.41M | 1.17B | 1.33B | 221.13M | 584.31M | 401.21M | 369.41M |
| Interest Expense | 4.11B | 3.33B | 2.28B | 3.81B | 4.59B | 2.67B | 1.11B | 736.03M | 290.44M | 761.15M |
| Depreciation & Amortization | 5.03B | 4.81B | 3.30B | 2.78B | 2.35B | 2.28B | 2.65B | 2.55B | 3.61B | 3.43B |
| EBITDA | -40.88B | -29.54B | -22.17B | 48.00B | 6.56B | -29.12B | -15.57B | -27.65B | 8.70B | 2.12B |
| EBITDA Ratio | -923.46% | -183.04% | -60.21% | -220.46% | -391.66% | -314.26% | -85.08% | -249.63% | 14.43% | 11.98% |
| Operating Income | -41.24B | -34.41B | -25.47B | -43.66B | -46.62B | -42.76B | -26.86B | -30.89B | 1.09B | -2.68B |
| Operating Income Ratio | -931.65% | -213.23% | -69.17% | -235.47% | -412.43% | -331.98% | -94.39% | -272.07% | 3.34% | -42.93% |
| Total Other Income/Expenses | -8.78B | -23.15B | -29.19B | 66.70B | 44.16B | 4.02B | 7.53B | -47.48M | 3.72B | 596.78M |
| Income Before Tax | -50.02B | -7.00B | -27.09B | 42.29B | -371.59M | -34.07B | -19.33B | -30.93B | 4.80B | -2.10B |
| Income Before Tax Ratio | -1,129.99% | -43.38% | -73.55% | 228.05% | -3.29% | -264.46% | -67.93% | -272.49% | 14.77% | -33.53% |
| Income Tax Expense | 16.84B | -857.24M | -834.48M | -33.83M | 16.14B | 0.00 | 0.00 | 0.00 | 5.83B | 0.00 |
| Net Income | -66.87B | -56.27B | -47.73B | 27.57B | -16.51B | -34.07B | -19.33B | -30.93B | -1.43B | -2.10B |
| Net Income Ratio | -1,510.71% | -348.69% | -129.59% | 148.68% | -146.06% | -264.46% | -67.93% | -272.49% | -4.39% | -33.53% |
| EPS | -1.65K | -1.33K | -1.38K | 825.46 | -556.06 | -1.20K | -754.73 | -1.38K | -61.21 | -153.56 |
| EPS Diluted | -1.65K | -1.33K | -1.38K | 627.18 | -556.06 | -1.20K | -754.73 | -1.38K | -61.21 | -153.56 |
| Weighted Avg Shares Out | 40.48M | 42.43M | 34.70M | 33.40M | 29.69M | 28.30M | 25.61M | 22.42M | 23.31M | 13.65M |
| Weighted Avg Shares Out (Dil) | 40.48M | 42.43M | 34.70M | 33.97M | 29.69M | 28.30M | 25.61M | 22.42M | 23.31M | 13.65M |
Source: https://incomestatements.info
Category: Stock Reports